Silexion Therapeutics Corp. has completed a 1-for-24 reverse stock split of its ordinary shares, as disclosed in a filing with the Securities and Exchange Commission dated November 12, 2026. The split was approved by shareholders at an extraordinary general meeting held on October 26, 2026, and became effective after the close of trading on November 10, 2026.
The reverse split reduced the number of issued and outstanding ordinary shares by a factor of 24. As a result of the transaction, the Company’s authorized share capital remains at $69,646,500, now consisting of 21,495,833 ordinary shares. The par value of each share increased from $0.135 to $3.24 per share.
Following the split, the Company’s ordinary shares began trading on a reverse split-adjusted basis on the Nasdaq Capital Market under the existing ticker symbol “SLXN” at the market open on November 11, 2026. The new CUSIP number for the ordinary shares is G1281K163.
The Company also notified holders of its warrants regarding adjustments made to their terms. The number of ordinary shares issuable upon the exercise of each warrant decreased proportionately to the reverse split ratio, meaning each warrant is now exercisable for 1/24th of an ordinary share. The exercise price for each warrant was increased 24-fold to $372,600.00 per post-split ordinary share. The Company stated that fractional shares resulting from warrant exercises will be rounded up to the nearest whole number, with the full exercise price required for that whole share. The trading symbol for the warrants remains “SLXNW,” and the CUSIP for the warrants remains G1281K114.
